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Abstract  
Given the implications of tumor dynamics for precision medicine, there is a need to 
systematically characterize the mode of evolution across diverse solid tumor types. In 
particular, methods to infer the role of natural selection within established human tumors 
are lacking. By simulating spatial tumor growth under different evolutionary modes and 
examining patterns of between-region subclonal genetic divergence from multi-region 
sequencing (MRS) data, we demonstrate that it is feasible to distinguish tumors driven 
by strong positive subclonal selection from those evolving neutrally or under weak 
selection, as the latter fail to dramatically alter subclonal composition. We developed a 
classifier based on measures of between-region subclonal genetic divergence and 
projected patient data into model space, revealing different modes of evolution both 
within and between solid tumor types. Our findings have broad implications for how 
human tumors progress, accumulate intra-tumor heterogeneity, and ultimately how they 
may be more effectively treated. 
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Introduction 
 
The multistage model of carcinogenesis described in the early 1950s 1,2 and 
Nowell’s 1976 perspective piece on the clonal evolution of tumor cells 3 provided a 
conceptual framework for understanding tumor progression. These and other studies 4,5 
were foundational in defining the elements of somatic evolution. However, the 
evolutionary dynamics that govern tumor initiation and subsequent growth after 
transformation remain poorly understood. Moreover, the distinction between stages is 
often blurred since tumorigenesis is largely occult often taking place over decades 6,7 
where lesions are only detected once they achieve a certain size or cause symptoms. 
Evolution is the product of three major underlying processes: mutation, selection 
and genetic drift 8. Mutations are readily measured in human tumors, and it is generally 
assumed that ongoing strong selection governs the growth of an established tumor after 
transformation, leaving a detectable signal on the genome, where the acquisition of 
additional ‘drivers’ results in multiple selective sweeps 9,10. In this scenario, driver 
mutations accompanied by numerous hitchhiking passengers can attain high frequency 
and manifest as ‘subclonal clusters’ in bulk tumor sequencing data 10. This led to the 
development of a suite of methods aimed at inferring subclonal clusters. However, 
inference of the number of subclones and their proportions from bulk tumor sequencing 
is a non-trivial task with the solution non-identifiable under most conditions 11-14. Drift 
can also cause extensive intra-tumor heterogeneity (ITH) that may be difficult to 
distinguish from selection without appropriate population genetics methods. For 
example, we proposed and tested several predictions of a Big Bang model of colorectal 
tumor growth, wherein after transformation, the tumor grows as a single terminal 
expansion populated by a large number of heterogeneous—and effectively equally fit—
subclones 15.  In this model, most detectable subclonal (private) alterations arise early 
during growth. While post-transformation selection could be detected in these colorectal 
tumors, it was often too weak to alter tumor subclonal architecture. Rather, patterns of 
ITH were suggestive of effectively-neutral evolution.   
Other studies have since corroborated ‘Big Bang’ dynamics in colorectal tumors 16-
19. Additionally, neutral evolution was reported in hepatocellular carcinoma via in depth 
multi-region profiling 20. Williams et al. further investigated evidence for neutral evolution 
in multiple solid tumors using bulk single sample sequencing data compared to a 
theoretical null neutral model 21. However, as we show, this task is better powered using 
MRS, which captures additional features of genetic diversity.  
Progression modes and tempos differ between neutrally evolving tumors and those 
tumors with post-transformation selection. Hence, there remains a need for the 
systematic evaluation of different modes of evolution in diverse solid tumors within a 
population genetics framework.  As selection is complex, it is instructive to initially focus 
on the commonly assumed scenario of strong positive selection after transformation and 
contrast this with a neutral model. We leverage the fact that spatiotemporal patterns of 
genetic variation among cancer cell populations and in particular their variant allele 
frequency (VAF) distributions (also known as the site frequency spectrum or SFS) 22 
derived from next generation sequencing (NGS) can be used to test hypotheses about 
the underlying evolutionary processes, including the strength of selection and extent of 
genetic drift. To this end, we simulated spatial tumor growth under different modes of 
evolution and trained a classifier based on ITH metrics derived from the SFS to 
discriminate between these scenarios. By projecting MRS data from various solid 
tumors into model space, we categorize their patient-specific evolutionary dynamics.  
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Results 
Spatial simulation of distinct modes of tumor evolution  
To investigate how different modes of tumor evolution influence the SFS from bulk 
sequencing data, as well as the power to detect signals of positive selection, we 
developed an agent-based model of spatial tumor growth (parameters reported in 
Supplementary Table 1). Within this framework, we simulated various modes of tumor 
evolution, including a neutral model and an alternate neutral model based on cancer 
stem cell (CSC) driven growth (neutral-CSC). We also simulated various levels of 
positive selection (s=0.01, 0.02, 0.03, 0.05, 0.1), such that the acquisition of 
advantageous mutations alters the cell birth-death rate according to the selection 
coefficient, s (Figure 1, Supplementary Figure 1, Methods). In all models random 
neutral point mutations arise via a Poisson process during each cell division. Virtual 
tumor growth is simulated via the expansion of deme 23 subpopulations (i.e. 
neighborhoods of 5-10k cells) within a defined 3D lattice, and cells within each deme 
are well-mixed and replicate via a random branching process. By recording mutational 
lineages as the tumor expands and subsequently virtually sampling the ‘final’ tumor as 
is done experimentally after resection, we evaluate differences in the SFS arising under 
different levels of selection, and the utility of different tissue sampling strategies (Figure 
1a). Thus, we model spatial tumor growth and the inherent stochasticity of this process 
while accounting for the truncated SFS derived from bulk sequencing due to the large 
number of rare subclones that are not sampled or below detection limits. This facilitates 
comparisons with data derived from patient tumors analyzed within a sensitive pipeline 
for calling somatic single nucleotide variants (SSNVs) from MRS (Figure 1b, 
Supplementary Figure 2, Methods). A summary of terminology is provided in 
Supplementary Table 2.	
Spatial subclone composition and the distribution of subclonal VAFs derived from 
MRS (n=2, 4 and 8 regions) of ‘virtual’ tumors differed dramatically depending on the 
mode of evolution, as illustrated for representative virtual tumors (Figure 2ab, 
Supplementary Figure 3). In particular, under stronger selection (s≥0.02), multiple 
subclone expansions occur in different regions of the virtual tumor, as shown in the 
clone map (Figure 2a). Likewise, multiple peaks (mutational clusters) were observed in 
the SFS histograms due to the enrichment of high frequency (VAF>0.2) subclonal 
SSNVs under stronger selection (Figure 2b and shown schematically in 
Supplementary Figure 4), which were largely region-specific, reflecting elevated 
genetic divergence. Indeed, subclonal selection typically resulted in detectable 
differences in the SFS histograms from different tumor regions. In contrast, under 
neutral growth, a neutral CSC-like model where only a subset of cells have unlimited 
proliferative potential (equivalent to a smaller deme size), or weak selection (s=0.01), 
subclonal composition is preserved in the final tumor. The SFS for these three modes 
were generally similar between regions consisting of two ‘mutational clusters’, namely a 
public cluster centered at 0.5 VAF composed of mutations that occurred prior to 
transformation and present in all tumor cells (fixed) and a right skewed distribution of 
private (subclonal) mutations at low VAF (<0.25) (Figure 2b), where their detection 
depends on sequencing depth. Importantly, MRS but not single-sample sequencing 
enables the identification of private SSNVs present at high frequency in one or a few 
regions, but subclonal in the entire tumor (Supplementary Figure 4). Indeed, at least 
two spatially separated regions are needed to accurately distinguish public SSNVs in 
solid tumors, as mutations that are subclonal in the whole tumor can appear ‘clonal’ 
within some samples due to sampling bias 24. In each of the modes, over	 70% of 
subclonal SSNVs were region-specific due to spatial constraints during virtual tumor 
	 5	
expansion. However, selection increased the fraction of high frequency (VAF>0.2) 
region-specific subclonal SSNVs out of all region-specific subclonal SSNVs (VAF>0.08) 
(fHrs) (Supplementary Table 4). Hence, MRS aids the identification of subclonal 
SSNVs that reflect the dynamics of clonal expansion after tumor transformation, 
whereas clonal SSNVs are not informative in this regard.  
To quantify the extent of ITH defined as between-region genetic divergence based 
on subclonal SSNVs (identified through MRS) under different levels of selection, we 
employed the following metrics (Methods) in addition to fHrs (defined above): 
fHsub – fraction of subclonal SSNVs (VAF>0.08) with high frequency (VAF>0.2). 
FST (Fixation index) – a measure of genetic divergence between regions 25.  
KSD (Kolmogorov-Smirnov distance) – dissimilarity of the SFS between regions. 
As expected, fHrs and fHsub were correlated, as were other features, albeit to a lesser 
extent (Supplementary Figure 5). All of the statistics increased in value under stronger 
selection (s≥0.02) relative to the neutral/neutral-CSC/weak selection (s=0.01) models. 
This suggests that selection causes characteristic and detectable genetic divergence 
between regions when it fails to result in complete sweeps (Figure 2b, Supplementary 
Table 4).  
We further explored the relationship between different modes of evolution and 
genetic divergence captured by MRS (n=2,4,8 regions) and single sample sequencing 
at various depths (80-640x) (Figure 2c, Supplementary Figures 6-7, Methods). For 
reference, the theoretical cumulative SFS assuming neutral exponential growth in a 
well-mixed population 21,26 (referred to as the theoretical neutral SFS) is also shown. 
Differences in the SFS were evident such that tumors simulated under higher selection 
(s≥0.02) typically fell above the theoretical neutral SFS, whereas the remaining modes 
generally traced or fell below this curve. The variability in the SFS within individual 
modes highlights the importance of stochastic simulations.  
To compare the utility of single sample data versus MRS, we computed the ratio of 
the area under the cumulative SFS (based on the pooled VAF for MRS) to the area 
under the theoretical neutral SFS (rAUC) as this is applicable to both single sample and 
MRS. Comparison of the rAUC for virtual tumors simulated under different modes 
demonstrates the challenge of distinguishing between s>0.05 or s£0.01 (including the 
neutral and neutral-CSC models) with a single sample, even at high depth, whereas 
better separation is achieved with even one additional region (Supplementary Figure 
8). This is also reflected in comparisons of the sensitivity and specificity to distinguish 
alternative models from the simulated neutral model based on the rAUC 
(Supplementary Figure 9a). Whereas power increased with selection intensity (s=0.05-
0.1) and the number of regions (n=2-8), this was not the case for increased depth alone 
due to sampling bias and the inability to capture regionally localized high frequency 
subclonal mutations that arose under strong selection (Supplementary Figure 9b, 
Methods). In contrast, metrics that capture between-region ITH such as fHsub are better 
able to distinguish a specific alternate model than rAUC. Of note, s=0.01 could not be 
distinguished from the simulated neutral model. The neutral-CSC model is also similar 
to the ‘vanilla’ neutral model, but generates localized diversity. Thus, we refer to these 
three modes as effectively-neutral, since the population dynamics of such nearly neutral 
mutations are virtually equivalent to those of neutral mutations 27,28. Similarly, it was not 
feasible to distinguish the SFS under different levels of elevated selection (s≥0.02) 
(Supplementary Figure 5). Many factors can dampen signals of selection as in the 
case of strong, but less frequent ‘drivers’ that are very rare or occur late without 
sufficient time to expand (Supplementary Figure 10). As such, we focus on effective 
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neutrality and strong selection (s≥0.02), but present results from all modes for 
completeness.  
 
The site frequency spectrum reflects tumor growth dynamics  
In order to evaluate the SFS in patient samples, we first analyzed MRS data from 
colorectal adenocarcinomas sampled from two regions (COAD, taken >3 cm apart) 15 
with high purity (72-96%) and adequate coverage (80-120X median WES depth) 
(Supplementary Figures 11-12). We devised a MuTect-based Variant Assurance 
Pipeline (VAP) to enable the sensitive and accurate detection of subclonal SSNVs from 
MRS (Supplementary Figures 2, 13, Methods and Supplementary Note). The 
observed VAF estimates were adjusted for sample purity and local copy number, 
enabling pairwise comparisons between tumor regions, and throughout we refer to 
adjusted VAFs as VAFs (Supplementary Figures 14-15). As noted above, the SFS 
histograms appear bimodal for both regions, as shown for representative tumors from 
the major COAD subgroups, namely microsatellite instable (MSI-H), microsatellite 
stable/chromosomally stable MSS/CIN- and MSS/CIN+ 29 (Figure 3a). A peak centered 
at a VAF of 0.5 was observed in all tumors with constituent mutations that were present 
at similar frequencies in the left and right samples (Figure 3b). This VAF cluster 
primarily represents public mutations present in the founding tumor cell. Whereas 
private high-VAF (0.2-0.4) SSNVs were infrequent, low frequency subclonal SSNVs 
(VAF<0.2) were common and generally region-specific despite having similar VAF, 
suggesting that mutation frequency is not a reliable surrogate for subclone identity. 
Similar patterns were observed in additional cancers and an adenoma (Supplementary 
Figure 15). We computed the five ITH metrics, which exhibited low or intermediate 
values for COADs M, O, and U comparable to those noted in ‘virtual’ tumors under 
effectively-neutral growth. In contrast, tumors G, N, W, and adenoma S exhibited higher 
values, similar to those noted in ‘virtual’ tumors subject to selection (Figure 3, 
Supplementary Tables 4-5).  
We further evaluated the genetic divergence within a clonal in vivo tumor growth 
model by generating single cell expansions from mismatch repair (MMR) deficient 
COAD cell lines followed by xenotransplantation into opposite flanks of immune 
compromised mice and WES of the resultant tumors (Methods). In both technical 
replicates and independent cell line experiments, the data yielded SFS histograms that 
lacked enrichment for high-frequency private SSNVs (Supplementary Figures 16-17). 
Additionally, the corresponding ITH metrics were congruent with effectively-neutral 
growth, as might be expected for fully transformed cells that do not require further 
alterations to propagate tumor growth.  
 
VAF clusters do not necessarily capture subclone identity  
Existing computational methods to infer tumor subclonal architecture from bulk 
sequencing data exploit the observation that SSNVs cluster around several distinct VAF 
modes or  ‘clonal clusters’ 10-13,30. These methods aim to assign ‘subclone’ identity 
based on the assumption that mutations with similar frequencies are in the same cell 
and that	 a limited number of dominant subclones underwent clonal expansion 9,11,31. 
However, mutational clusters do not guarantee unique lineages, and therefore do not 
necessarily capture clonal identity. In addition, subclone architecture is influenced by 
the mode of tumor evolution and spatial constraints. Indeed, visual inspection of the 
SFS histograms and scatterplots from the bi-sampled COAD dataset revealed that in all 
cases, the majority of subclonal SSNVs with VAF<0.2 were region-specific (Figures 3, 
Supplementary Figure 15). This suggests that mutations grouped based on their VAF 
do not correspond to unique clones. To evaluate subclonal architecture at higher 
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resolution, we performed WES on five individual COAD glands and bulk samples from 
two distant tumor regions of a representative cancer (COAD O). The private mutations 
specific to either bulk sample (OA or OB, Figure 4a, b) were only detected in glands 
from the same tumor region (p=1E-10, Fisher’s exact test) and similar patterns were 
noted based on targeted sequencing of private SSNVs in multiple individual glands for 
each of the bi-sampled COADs (Supplementary Figure 18). In a subset of single 
glands from two spatially separated regions, the same SSNVs were detected despite 
being subclonal in the bulk tumor (Figure 4b, green dots), potentially reflecting early 
subclone mixing 15,19 or sampling of a clone boundary. In contrast, later arising SSNVs 
were generally restricted to one region, consistent with spatial constraints during 
expansion.	 SSNVs specific to bulk sample OA (VAF < 0.2) were detected in different 
combinations of single glands with VAF > 0.2, suggesting that distinct lineages can have 
similar VAFs in the bulk tumor. Reconstruction of a possible phylogenetic tree using 
LICHeE 32 also revealed subclone spatial segregation, where essentially every gland 
within a bulk region is a subclone (Figure 4d), emphasizing the star-like phylogeny 
predicted for a neutrally growing population 26 (Supplementary Figure 19). WES of 
single glands from COAD U yielded similar results (Supplementary Figure 20).  
We further reasoned that a ‘true’ clone should form a cluster that persists (e.g. 
mutations remain grouped), irrespective of the inclusion of data from additional regions.  
We evaluated this in other solid tumors by analyzing published MRS datasets for 
esophageal carcinoma (ESCA) 33, lung adenocarcinoma (LUAD) 34, non-small cell lung 
cancer (NSCLC) 35, glioma (GLM) 36 and glioblastoma (GBM) 37 (Supplementary 
Figure 2, 11, Supplementary Table 3, Methods). Application of SciClone 13 to MRS 
data from several representative tumors (COAD-O, ESCA-8, LUAD-4990 for which 2, 3 
and 4 regions were available, respectively) consistently resulted in the separation of 
subclonal clusters when data from additional regions were included in the analysis 
(Figure 4c, Supplementary Figures 21-23). Whereas SSNVs in the subclonal clusters 
did not remain grouped, those in the clonal clusters did (p=0.0003, Fisher’s exact test), 
consistent with them being in the founding clone. A persistent mutational cluster in 
LUAD-4990 was detected through the analysis of 4 regions, potentially corresponding to 
a subclone that arose under selection (Supplementary Figure 22). Collectively, these 
results illustrate conceptual challenges in inferring subclonal architecture from bulk 
sequencing VAF data alone.  
 
Distinguishing the mode and tempo of solid tumor evolution 
We next evaluated genetic divergence based on MRS of treatment naïve primary 
tumors, including COAD, ESCA, LUAD, LUSC, and GBM relative to those observed in 
virtual tumors under different modes. Non-hypermutated GBMs (n=2) and gliomas (n=2) 
obtained pre- and post-treatment with temazolamide, a mutagenic alkylating agent 
assumed to impose a positive selective pressure 36, were included as positive controls. 
Additionally, matched Barrett’s esophageal (BE) lesions and adenocarcinomas from two 
patients (BE-ESCA-4 and BE-ESCA-14) were included as positive controls, since 
selection is expected during progression from a pre-malignant lesion. The degree of 
deviation of the pooled cumulative SFS above the theoretical neutral curve highlights 
differences in selection across tumor types (Figure 5a). As predicted, each of the 
positive controls exhibited cumulative SFSs above the neutral curve, consistent with 
strong selection. In contrast, deviation below the theoretical neutral curve is indicative of 
spatial constraints, as illustrated by simulating smaller deme sizes (0.5-1k vs. 5-10k), 
where the ability to distinguish selection from effective neutrality was reduced 
(Supplementary Figures 24-25). Such strong spatial constraints result in infrequent 
sharing of subclonal mutations between regions (fShr, Supplementary Table 4-5), a 
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pattern inconsistent with most patient tumors (p < 2.2e-16, Wilcoxon rank sum test), 
suggesting that larger deme size better reflects the patient data.  
COAD-M and ESCA-14 exhibited bimodal SFS histograms with scant enrichment 
for high frequency private SSNVs, most consistent with patterns of effective neutrality 
(Figure 5b). In contrast, COAD-N and LUAD-270 exhibited modest enrichment for such 
SSNVs, whereas this was more striking in ESCA-8 and LUAD-4990. Despite the lower 
number of SSNVs in treatment-naïve primary GBMs, enrichment of high frequency 
private SSNVs was evident and similar to that noted in the primary versus post-
treatment recurrence (Figure 5b). 
The five ITH metrics were calculated for primary solid tumors, paired pre- and post-
temazolamide treated gliomas and GBMs (positive controls) and BE-ESCA pairs 
(positive controls), as well as virtual tumors simulated under various evolutionary modes 
(Figure 6a). Amongst the virtual tumors, all five metrics increased markedly under 
selection (s≥0.02) relative to effective neutrality. The primary COADs and ESCAs 
tended to exhibit lower detectable divergence than lung and brain cancers, which were 
lower than the temazolamide treated positive controls.  
The SFS is commonly used in population genetics 22,38 and it is appreciated that 
tests of neutrality based on a single summary statistic can be difficult to establish, 
whereas composite metrics can aid the detection of selection 39. Given the multi-faceted 
nature of ITH and the noise in real data, we reasoned that the major components of the 
ITH metrics would capture complementary aspects of subclonal genetic divergence. 
Independent component analysis (ICA) using the five ITH metrics revealed two distinct 
clusters, corresponding to selection with s≥0.02 and neutral/weak selection 
(s=0.01)/neutral-CSC (Figure 6b). A support vector machine (SVM) was trained on the 
two independent components (ICs) to discriminate between effectively-neutral evolution 
(3 modes with s≤0.01) and selection (4 modes with s≥0.02). The SVM based on the ICs 
performed better than individual ITH metrics and although models using two or more 
ITH metrics performed well (Supplementary Figures 26-27), we adopted the two ICs to 
survey genetic divergence in patient samples.  
We then classified patient tumors and visualized them in model space (Figure 6b, 
Supplementary Figures 28-29, Supplementary Table 5), revealing trends with 
respect to the mode of evolution in a given tumor type, despite patient to patient 
variability. For example, COADs exhibited both effective neutrality as well as selection, 
as did ESCAs. In contrast, lung and brain tumors tended to show stronger signals of 
selection. In total, 5 primary tumors were categorized as being compatible with 
effective-neutrality and 12 with selection, whereas only 3 did not robustly fit either 
scenario. As expected, all four pre- versus post-temazolamide treated GBMs and 
gliomas were most compatible with strong positive selection and several appear as 
outliers on the ICA, potentially because the full impact of treatment is not modeled 
(Figure 6b). The paired BE-ESCA cases (ESCA_BE-14 and ESCA_BE-4) exhibited 
patterns consistent with selection during tumorigenesis, followed by effectively-neutral 
growth of the primary (ESCA-14 and ESCA-4). Patterns of genetic divergence in 
multiple BE lesions from patient 4 (BE-4) were similarly indicative of selection 
(Supplementary Figure 30). Importantly, irrespective of whether WGS or WES data 
was used, the classification was the same indicating that WES is adequate for this task 
given sufficient subclonal SSNVs (Figure 6b). 
Positive selection for ‘drivers’ during tumor expansion is expected to be associated 
with an increase in the rate of private SSNVs at more functional (MF) relative to less 
functional (LF) sites 40. Amongst primary tumors, the dMF/dLF ratio was positively 
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correlated with several ITH metrics, e.g., fHsub, FST, and rAUC (Figure 6c). This 
suggests a general trend between selection and the levels of detectable between-region 
genetic divergence, although specific patterns could be model dependent 
(Supplementary Figure 31). Conversely, the fold enrichment for driver genes amongst 
non-silent public SSNVs was negatively correlated with fHsub, consistent with a greater 
number of public drivers in tumors characterized by effectively-neutral growth 
(Supplementary Figure 32). Hence, these results corroborate our finding that patterns 
of genetic divergence in MRS inform the mode and drivers of tumor growth. 
  
Discussion 
Here we show that tumors evolving near neutrally or through strong selection exhibit 
fundamentally different patterns of ITH and that these can be distinguished via MRS. 
Further, we developed a classification framework based on features of the SFS that 
capture between-region subclonal divergence and applied this to publicly available MRS 
data, revealing different modes of evolution within and between solid tumor types. We 
note that compatibility with effective neutrality does not necessarily imply the complete 
absence of selection. Rather, selection may have been weak or variable throughout 
tumor growth, but the overall patterns do not deviate significantly from those expected 
under a neutral model. The timing of a mutation is also critical since within a rapidly 
expanding adaptive population, only mutations that occur early are likely to be ‘fixed’ in 
relevant time frames and detectable by NGS, even if they are under strong positive 
selection, whereas partial sweeps are potentially common 41. The lack of evidence for 
ongoing stringent selection in some of the tumors examined here is congruent with a 
Big Bang model of effectively-neutral tumor growth where the tumor grows as a single 
expansion with selection uniformly conferred by common drivers in the first tumor cell 15.  
The finding that human tumors can be categorized into different modes of evolution 
has implications for defining the ‘drivers’ of growth and treatment strategies. For 
example, near-neutrally evolving tumors show enrichment for drivers amongst public 
SSNVs, and it is potentially most efficacious to target these truncal mutations. While 
most detectable ITH occurs early during effectively-neutral growth, the large number of 
heterogeneous subclones that fall below detection limits increases the chance that pre-
existing treatment resistant variants are present. In contrast, putatively functional private 
variants were enriched amongst tumors characterized by ongoing positive selection, 
suggesting these may represent relevant targets. 
Our findings also inform practical guidelines for studies of tumor evolution. For 
example, we show that while at least two regions are required to robustly distinguish 
public versus private alterations, inclusion of sequencing data from additional regions 
yielded greater discrimination between different modes of evolution and was more 
informative than deeper sequencing of a single sample. Even under strong spatial 
constraints such as small (0.5-1k) deme size, where the efficacy of selection is 
impeded, sequencing additional regions should aid the detection of selection. Improved 
sensitivity to distinguish different modes of evolution may be achieved by modeling the 
distinct architecture and microenvironments in different tissues, although these are as of 
yet poorly understood 42.  It will also be important to understand the contribution of 
deleterious passenger alterations 43 and clonal cooperation 44,45 to tumor dynamics, as 
well as to evaluate more complex modes of selection in human tumors. Thus, although 
MRS does not fully resolve the SFS, it nonetheless captures global and local genetic 
divergence, enabling the detection of signals of selection in individual under certain 
conditions.	
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Online Methods 
Multi-region sequencing studies  
We evaluated patterns of ITH in several publicly available MRS datasets spanning 
multiple tumor types, including colorectal adenoma/adenocarcinoma (1 adenoma, 6 
COAD patients) 15, esophageal carcinoma/Barrett’s esophageal (ESCA, 3 patients) 33, 
lung adenocarcinoma (LUAD, 4 patients) 34, non-small cell lung cancer (NSCLC, 1 
patient) 35, glioma (GLM, 3 patients) 36, and glioblastoma (GBM, 2 patients) 37, numbers 
refer to cases with MRS data that passed QC. The study accession IDs and list of 
samples that met coverage and purity requirements are reported in Supplementary 
Table 3. Details on sequencing depth and purity are provided in Supplementary 
Figure 11. All samples were analysed using a custom pipeline (Supplementary Note) 
to enable the sensitive detection of private SSNVs and standardized comparisons 
across cohorts, as detailed below.  
 
Single gland whole-exome sequencing 
Building on our prior description of multi-region WES of colorectal tumors and 
targeted single gland sequencing, we performed WES of multiple single glands from two 
tumors in this study (Figures 4, Supplementary Figure 20) on the Illumina platform 
using the Agilent SureSelect 2.0 or Illumina NRCE kit. Samples were collected under an 
IRB approved protocol as previously described 15. The single gland WES data were 
analyzed using the same pipeline as was applied to bulk tumor regions. Intersection 
plots for SSNVs found in bulk regions and single-glands were generated based on 
mutations that were i) covered by at least 20 reads in each sample; ii) with a VAF above 
1.5% in the bulk sample or above 15% in the single-glands; and iii) do not derive from 
regions with varying patterns of LOH amongst samples.  
 
In vivo modeling of colorectal tumor growth  
Cells were expanded in vitro and a single ‘founding’ cell from this population was 
cloned and expanded to ~6 million (M) cells prior to transplantation of ~1M cells into the 
right and left flanks of a NSG mouse (HCT116) or a Nude (Nu/Nu) mouse (LoVo), 
where tumors were allowed to develop to a size of ~1 billion cells (1 cm3) before being 
sampled and subject to WES (Figures 3, Supplementary Figure 16-17). The HCT116 
and LoVo MMR-deficient COAD cell lines were obtained from the ATCC (authenticated 
using cytochrome C oxidase I assays and STR typing and tested for mycoplasma 
contamination) and cultured under standard conditions. Tissue was collected separately 
from the right and left tumors and DNA was extracted for WES using the Illumina 
TruSeq Exome kit, as was DNA from the first passage population (a polyclonal tissue 
culture for HCT116 and a polyclonal xenograft sample for LoVo), which were employed 
as a reference for detecting SSNVs and for CNA estimation.  
 
Somatic SNV calling, SCNA detection and VAF adjustment 
To facilitate quantitative comparisons of the SFS, we devised a unified variant 
assurance (filtering and rescuing) pipeline (VAP) to achieve balance in sensitivity and 
specificity when MRS is available such that information can be borrowed across tumor 
regions. For each raw SNV call by MuTect (v1.1.4, unfiltered) 46, the read alignment 
features from all samples was re-inspected in an automated fashion to assess the 
confidence (in detected samples) and evidence (in un-detected samples) for the 
alternative allele (Supplementary Figure 13).  Somatic copy number alterations and 
tumor purity (!) were estimated with TitanCNA 47 (version 1.8.0) in exome-seq mode 
(except for the ESCA dataset where WGS was available). The observed VAF for each 
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detected somatic SNV was adjusted based on CCF (Cancer Cell Fraction) calculation 
by taking into account tumor purity, local copy numbers as well as the inferred time 
ordering between SCNA and SSNV as previously described 31 (Supplementary Figure 
14-15), in order to enable comparisons of genetic divergence between regions. 
Additional details for this section, including benchmarking of VAP (Supplementary 
Figure 33-35), can be found in the Supplementary Note. 
 
Spatial computational modeling of tumor growth dynamics Ino 
We extended our previously described spatial agent-based model 15 to simulate 
tumor growth and mutation accumulation under different scenarios ranging from neutral 
evolution to strong selection and compare the SFS of SSNVs arising from 1, 2, 4 and 8 
regions sampled from spatially separated quadrants of individual virtual tumors. In this 
agent-based model, spatial tumor growth is simulated via the expansion of deme 
subpopulations (composed of 5-10k cells), which mimics the glandular structures often 
found in epithelial tumors (Supplementary Table 1). The deme model is well 
established for modeling spatially expanding populations 23. Here, deme subpopulations 
expand within a defined 3D cubic lattice (Moore neighborhood, 26 neighbors), where 
demes expand by particular rules of spatial constraints (peripheral growth 48 or 
alternatively shifting growth 15) while cells within each deme are well-mixed and grow via 
a random branching (birth-death) process. The panmixia	of cells in the formation of the 
first deme from a single transformed cell allows for subclone mixing amongst early-
arising mutations 15,19, which can subsequently spread during tumor expansion. 
Random neutral mutations arise via a Poisson process at each cell division, assuming 
an infinite sites model.  
More specifically, at each time step, we simulate deme division by selecting a deme 
at random and choosing a neighboring lattice site where the new deme will be placed. 
We employ a peripheral growth model 48 (Supplementary Table 1), where only demes 
on the surface of the tumor can grow and divide such that a random empty neighbor site 
was chosen for each newly generated deme. The peripheral growth model is supported 
by recent studies indicating that cancer cells at the periphery of the tumor exhibit higher 
proliferative activity than those at the core 42. We assume a maximum deme size of 
10,000 cells in order to minimize the effect of deme structure, which hinders selection. 
While we focus on this conservative scenario, we also explored the impact of a smaller 
deme sizes (down to 1,000 cells) (Supplementary Figures 24-25).  Within the model 
there is no spatial partition for tumor cells within demes which proliferate via a discrete 
stochastic birth-and-death process (division rate p and death rate q=1-p, the death/birth 
ratio h=q/p), where the first deme is generated by the same process beginning with a 
single transformed tumor cell. Simple birth-death processes give rise to exponential 
growth of each deme on average where the growth rate is r=ln(2p). Here we employ the 
following parameters: p=0.55, q=0.45 and thus r=ln(2×0.55)≈0.1 as the growth rate of 
deme expansion, where p and q were empirically chosen by assuming a relatively high 
death versus birth rate (h=q/p=0.82) in each cell generation in line with previous 
estimates in a rapidly growing colorectal cancer metastasis (h=0.72) 49 and in early 
tumors (h=0.99) 50. Once the deme exceeds the maximum size, the deme will split into 
two offspring demes via sampling from a binomial distribution [Nc, p=0.5] where Nc is 
the current deme size. During each cell division, the number of neutral passenger 
mutations that arise in the coding portion of the genome follows a Poisson distribution 
with mean, u, where an infinite sites model and constant mutation rate was assumed. 
Under the null model, all somatic mutations are assumed to be neutral and do not 
confer a fitness advantage, whereas in the selection models, beneficial mutations (or 
advantageous mutations) occur stochastically via a Poisson process with mean ub 
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during each cell division. Thus, we consider the null neutral model (s=0), as well as 
varying degrees of selection: s=0.01, 0.02, 0.03, 0.05 and 0.1, where s is the selection 
coefficient defined by the increase in the cell division rate when a beneficial mutation 
occurs in the neutral cell lineage. The cell division rate and death rate of a selectively 
beneficial clone is pb=p×(1+s) and qb=1-pb=1-p×(1+s), respectively. The growth rate of a 
selective lineage within a deme is rb=ln(2*pb). The parameters employed are reported in 
Supplementary Table S1 and include u=1.2 within the 60 Mb of coding sequence in a 
diploid genome corresponding to a mutation rate of 2×10-8 per cell division per site. For 
the selection models, we assume ub=10-5 per cell division for driver mutations, on order 
with that previously suggested by Bozic et al. 50. We also investigated the impact of a 
lower selectively advantageous mutation rate (ub=10-6) on the SFS, as this mimics late 
arising driver mutations (Supplementary Figure 10).  
We also sought to explore how a naïve model of neutral cancer stem cell (neutral-
CSC) driven tumor growth would influence the resultant SFS. Here, each deme 
comprises two subpopulations – stem cells (SCs) and non-SCs where the SC fraction is 
p(SC). In each cell generation, SCs divide symmetrically generating two SCs with 
probability α and asymmetrically generating one SC and one non-SC with probability β 
(where α+β=1 and thus the probability of symmetric SC differentiation is 0). Non-SCs 
can only divide with probability γ or die with probability δ (where γ+δ=1). We exploit a 
set of parameter values: namely α=0.15, β =0.85, γ=0.565 and δ=0.435 to ensure the 
maximum deme size is ~10,000 cells and the SC fraction p(SC)≈1-2%, consistent with 
estimates in solid tumors 51. While it is of potential interest to consider a CSC model in 
the context of selection, this is complicated by the need for additional parameters with 
little experimental support, and hence we do not investigate this here. 
During virtual tumor growth, each mutation was assigned a unique index and is 
recorded with respect to its genealogy and host cells during the simulation, enabling 
analysis of its frequency in a subpopulation or the whole tumor at different stages of 
growth. Once the tumor reached a final size of ~109 cells, approximately the size when 
it is detectable and routinely resected, we virtually sampled: 1, 2, 4, or 8 regions 
composed of ~106 cells from an individual virtual tumor (200 tumors under each of the 7 
evolutionary modes, totalling 1400 virtual tumors). The VAF of all SSNVs in the sampled 
bulk subpopulation were considered the true value, whereas observed VAF values were 
obtained via a statistical model that mimics the random sampling of alleles during 
sequencing. In particular, we applied a Binomial distribution (n, f) to generate the 
observed VAF of each site given its true frequency f and number of covered reads n. 
The number of covered reads in each site is assumed to follow a negative-binomial 
distribution. Here, we assume depth=80 representing 80x sequencing depth on average 
with a variation in parameter size of 2. A mutation is called when the number of variant 
reads is ≥ 3, thereby applying the same criteria as for the actual tumors. For each virtual 
tumor, 100 clonal SSNVs were assigned to represent public mutations, where VAF 
values were simulated using the statistical model described above with mean VAF of 
0.5. 
 
Identification of subclonal SSNVs in MRS  
A SSNS # is defined as subclonal if all of the three following criterion are met, 
1) A total probability  $% = $%'(')* +%' ≤ -%'	, 0%'	, 	1. !34%' < 0.05, where  $%' 
is a binomial probability for region 8 of observing less than or equal to  -%' reads 
carrying mutant allele out of total reads 0%', provided a lower bound of expected 
allele frequency if # is public, given that the tumor purity for region 8 equals to 
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!3', the total, minor copy numbers and the cellular prevalence of the SCNA 
where # resides equal to 9:%', 94%', and !;%' within the tumor content, 1. !34%' = !3'×94%'9=%' 																					81	94%' ≥ 1, 9=%' ≥ 2(!3'	×(9:%' − 94%')) 9=%' 											D:ℎFGH8IF 
where 9=%' = 9:%'×!;%'×!3' + 2×(1 − !;%'×!3'). For sites devoid of SCNAs, 9:%' = 2, 94%' = 1	;9K	!;%' = 0. 
2) At least one region 8 with 	LLM%' ± 95%	LQ%' < 1 
3) At least one region 8 with adjusted VAF RSMT%' < 0.25. Here 0.25 was chosen 
because of its good performance in defining subclonality based on simulated 
virtual tumors (Supplementary Figure 36). 
A SSNV that does not meet one of the above criterion is considered public. SSNVs with 
varying patterns of loss of heterozygosity (LOH) amongst regions were not included for 
pairwise SFS comparisons. The pooled cumulative SFS was computed when multiple 
samples were available. Here we employ an f_max of 0.25 as the upper value for 
subclonal mutations, whereas f_min depends on the total sequencing depth (and hence 
number of regions sequenced) and is chosen conservatively, while maximizing the 
inclusion of high confidence low VAF SSNVs.  
 
ITH metrics  
For pairwise comparisons between regions, subclonal (private) SSNVs were 
assigned as being either private-shared or region-specific. Private-shared SSNVs are 
present in both regions, whereas region-specific SSNVs are unique to one region where 
we reject a null model of the same VAF in the other region (given the sequencing depth) 
with a 5% significance level. For each pairwise SFS histogram, the bin width was 
optimized for visualization purposes based on the number of SSNVs 52. Metrics 
capturing between-region ITH were computed for U  regions and G = (V  pairwise 
comparisons as follows: 
1) 1WI34 = *( × XYZ[Z\[XYZ]^^(')*  , where-_'` 'a` , -_'Tbb  are the number of high frequency 
subclonal SSNVs (adjusted VAF>0.2, hereafter referred to as VAF) and the 
number of all subclonal SSNVs with VAF>0.08 for region 8. The cutoff was set to 
0.2 since above this value 1WI34 tends to plateau in its sensitivity to distinguish 
the neutral and selection models (Supplementary Figure 36). A lower cutoff of 
0.08 was chosen empirically to satisfy the tradeoff between the number of 
subclonal SSNVs and variant calling errors. 
2) 1WGI = *c × ( dXYe][Z\[V×dXYe]]^^ + dXYef[Z\[V×dXYef]^^)cg)*  , where h-_gT`'a` , h-_gTTbb  represent the 
number of high-frequency (VAF>0.2) region-specific SSNVs and the number of 
all region-specific SSNVs with VAF>0.08 for region ;, in a pairwise comparison i 
between regions ; and 4. 
3) M-j = *c × M-jg` klmnocg)* , and M-jg` klmno = 	 (p]qrpfq)srt]q× uvt]qw]qvu rtfq× uvtfqwfqvuqxqyu p]q× *rpfq zpfq× *rp]qqxqyu , 
where 1T%is the VAF for SSNV # and KT% is the sequencing depth for SSNV # in 
region ; . The genetic variance components (nominator and denominator) are 
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averaged separately to obtain a ratio combining the Hudson FST estimates 
across all #{	SSNVs 53. 
4) |-} = *c × |-}gcg)* , and |-}g = max MT − MÅ , where MT  is the cumulative SFS 
of region ;, in a pairwise comparison i between regions ; and 4. 
5) GSÇL = SÇL%ÉcaÉl SÇL{`Énc , corresponding to the ratio of the area under the 
pooled cumulative SFS to the area under a theoretical cumulative SFS assuming 
neutral exponential growth of a well-mixed population 21,26. For MRS, the pooled 
VAF is the total number of alternative alleles divided by total read depth. As this 
represents the alternative allele frequency pooled across tumor regions, it should 
capture overall tumor dynamics, but not between region diversity and 
complements other ITH metrics. 
To evaluate the power (at a significance level of 0.10) or sensitivity of ITH metrics to 
distinguish a specific alternate model from the neutral model in the simulated data given 
varying numbers of samples (n=1, 2, 4 and 8) or variable sequencing depths of a single 
sample (80-640x), we employed rAUC as it is applicable to single sample data, as well 
as fHsub, one of the MRS specific statistics. The power was computed empirically as 
the percentage of virtual tumors under an alternative model for which the statistic (rAUC 
or fHsub) was greater than 95% or less than 5% of the corresponding statistic in the 
neutral model (taking the larger percentage).     
 
Evolutionary mode classifier  
A radial basis function (RBF) kernel SVM was built based on 1,400 simulated 
tumors derived from seven growth models (200 for each of neutral, neutral-CSC, 
s=0.01, 0.02, 0.03, 0.05 and 0.1). We grouped virtual tumors simulated under the 
neutral, neutral-CSC and s=0.01 models as "effectively-neutral" and those simulated 
under higher selection coefficients (s≥0.02) as "selection" based on the distribution of 
the five statistics (Figure 6a). The five ITH metrics derived from the SFS were Z-score 
centered and scaled to have mean 0 and SD equal to 1. The SVM was trained using 10 
fold cross validation with the R package caret 54. Two rounds of training were performed 
to optimize the two parameters for RBF (C: the "cost" of the radial kernel and sigma: the 
smoothing parameter). In the first round, tuning parameters were arbitrarily selected and 
the default settings were used for the remainder. The training function was employed to 
calculate estimates for the parameters. In a second round, sensitivity analysis was 
performed to refine the parameter choice. To evaluate the relative importance of 
different combinations of the five ITH metrics for classification, SVMs were run 20 times 
for each of 26 possible combinations of five statistics with the same seed used for 
random splitting, where 4/5 virtual tumors were used for training and 1/5 for testing, and 
the resulting ROC AUCs were compared (Supplementary Figure 27). A SVM was also 
built using the two major independent components (IC) obtained from independent 
component analysis (ICA) of the five ITH metrics where the decision boundaries are 
shown on the ICA scatter plots. ICA was performed on features derived from the virtual 
tumors and patient tumors for n=2 (Supplementary Figure 28), n=4 (Figure 6b) and 
n=8 (Supplementary Figure 29) virtual tumor regions. The performance of the SVM to 
distinguish each alternative model from the neutral model was evaluated by comparing 
100 virtual tumors for training and 100 virtual tumors for testing (Supplementary Figure 
26). 
 
Functionality assessment of private and public SSNVs 
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The ratio of private SSNVs at more functional (MF) relative to less functional (LF) 
sites was determined as previously described 40 in order to evaluate the correlation 
between dMF/dLF and various ITH metrics derived from the SFS. SSNVs were 
considered MF if classified by Polyphen-2 as "damaging" or "probably damaging" and 
LF if classified as "benign". The dMF/dLF ratio was calculated by normalizing MF/LF for 
private SSNVs in each tumor to a background MF/LF ratio based on random 
substitutions in the mutated genes. We also determined the fold enrichment for driver 
genes (defined based on IntOGen v.2016.5) amongst non-silent public SSNVs and the 
correlation with various ITH metrics.  
 
Code availability 
Code for the simulation studies and the Variant Assurance Pipeline are available at: 
https://github.com/cancersysbio/VirtualTumorEvolution 
https://github.com/cancersysbio/VAP 
 
Data availability 
The single gland WES data and xenograft WES data are available at EMBL-EBI 
ArrayExpress under accession number E-MTAB-5547. Data from \previously published 
studies are available at: dbGAP: phs000178/GRU; European Genotype Phenotype 
Archive (EGA): EGAD00001001394, EGAD00001000714, EGAD00001000900, 
EGAD00001000984, EGAD00001001113; EMBL-EBI European Nucleotide Archive 
(ENA): PRJEB12737 
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Figures 
 
Figure 1. Overview of simulation framework and genomic data analysis pipeline. 
(a) Schematic overview of our agent-based computational framework to simulate 3D 
tumor growth (after transformation) under various modes of evolution, including neutral 
evolution (null model) and different levels of positive selection, followed by spatial 
sampling and multi-region sequencing of the virtual tumor. Tumor growth is simulated 
via the expansion of deme subpopulations within a defined 3D cubic lattice according to 
explicit rules dictated by spatial constraints, where cells within each deme are well-
mixed and grow via a stochastic branching (birth-death) process (Methods and 
Supplementary Figure 1). By simulating the acquisition of random mutations (neutral 
or beneficial), tracing the genealogy of each cell as the tumor expands and 
subsequently virtually sampling and sequencing the ‘final’ virtual tumor as is done 
experimentally after resection or biopsy, it is possible to evaluate differences in the site 
frequency spectrum (SFS) under different modes of selection and sampling strategies. 
Five Intra-tumor heterogeneity (ITH) metrics derived from the SFS were employed to 
distinguish between different evolutionary modes. (b) A unified sequencing analysis 
pipeline based on SSNV calling, copy number estimation, as well as stringent quality 
control was employed to obtain variant allele frequency (VAF) estimates adjusted for 
purity and local copy number for seven multi-region sequencing (MRS) datasets derived 
frompatient samples across diverse tissue types. The ITH metrics were similarly 
computed in patient tumor samples and compared to those observed in virtual tumors 
under different evolutionary modes.  
 
Figure 2. Characteristics of virtual tumors simulated under different modes of 
evolution. (a) A 2D visualization of a clone map in virtual tumors simulated under 
different modes of evolution, including the null neutral model (selection coefficient, s=0), 
a neutral model with cancer stem cell driven growth (neutral-CSC), and varying levels of 
selection (s=0.01, 0.05 and 0.1).  Colors correspond to distinct clones with high VAF (> 
0.4) in each deme subpopulation.  (b) Representative pairwise SFS histograms derived 
from two spatially separated regions (labeled A and B) within the same tumor are shown 
for tumors simulated under different evolutionary modes. SSNVs were classified as 
Public (gray), Private (Pvt)-shared (green), or Private-region specific (blue) based on 
their presence in the virtual MRS data (Methods). The total number of SSNVs detected 
in each region, as well as three ITH metrics are indicated, namely fHsub, FST, KSD. (c) 
The cumulative SFS derived from virtual tumors (100 shown for each mode) was 
computed based on the pooled VAF for subclonal SSNVs for four regions in the 
frequency (f) range 0.02–0.25. Curves are Bezier smoothed. The dashed curve 
corresponds to the average and the black curve to a theoretical cumulative SFS under 
neutral exponential growth in a well-mixed population. For each mode, the mean ratio of 
the area under the cumulative SFS from the virtual tumors compared to that of the 
theoretical cumulative SFS (denoted rAUC) based on 100 virtual tumors is indicated as 
are the 95% bootstrap confidence intervals. 
 
Figure 3. Colorectal tumors exhibit patterns of between-region genetic divergence 
consistent with effectively-neutral growth or selection. (a) Pairwise comparison of 
SFS histograms from each of three bi-sampled colon adenocarcinomas (COADs) 
representing the major molecular subgroups, including MSI-H (carcinoma W, right), 
MSS/CIN+ (carcinoma U, middle) and MSS/CIN- (carcinoma M, left). The pairwise 
histograms illustrate the number of SSNVs detected at a given VAF for the two tumor 
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regions shown above and below the x-axis. SSNVs were classified as Public (gray), 
Private (Pvt)-shared (green), or Private-region specific (blue). The total number of 
SSNVs detected in each region, as well as fHsub, FST, KSD values are indicated. (b) 
Scatterplots comparing SSNVs detected in each tumor region at a given VAF. The color 
of individual SSNV points corresponds to that in Panel A, and hues reflect the number 
of SSNVs in a square (0.02 on a side) centered on each SSNV, as depicted in the 
legend. Nonsilent SSNVs in predicted COAD driver genes are denoted by red circles 
with known drivers labeled. (c) Circos plot illustrating the predicted absolute total CN 
(Nt) and minor allele CN (Nb) for each tumor sample. Diploid segments are indicated in 
white for Nt (two copies) and Nb (one copy), while segments with copy number gain and 
loss are shown in red and blue, respectively, according to the scale bar. Tumor cell 
purity (Pu) as well as ploidy (Pl) estimates for each region are indicated on the 
corresponding concentric rings.  
 
Figure 4. Single-gland WES reveals spatial constraints amongst subclonal 
mutations. (a) Pairwise histogram of the SFS and SSNV scatterplots from two regions 
of COAD-O (OA vs. OB). (b) Intersection of SSNVs found in bulk regions and single-
glands. In the inset, the VAFs for single-gland vs. bulk sample OA (side-A) specific 
SSNVs are shown. OA specific SSNVs present in different sets of single-glands 
collapse to similar VAF values (<0.2) in the bulk sample (blue lines connecting the 
insert), indicating that mutational clusters do not guarantee clonal identity. (c) The 
subclonal cluster of pooled VAF of LUAD-4990 partitioned into multiple clusters for VAF 
in two separate regions, whereas the clonal VAF cluster (centered at 0.5) persists as a 
single cluster, consistent with them being present in all cells. Generally, subclonal 
clusters derived from ‘n’ regions (for COAD-O, LUAD-4990 and ESCA-8) separate into 
additional clusters (with more than 5% SSNVs in the original cluster) when ‘n+1’ regions 
are employed in analysis (Supplementary Figures 21-23). (d) Phylogenetic tree based 
on SSNV presence/absence in single glands and bulk samples constructed using 
LICHeE. The bulk sample and corresponding single-glands from the same tumor region 
share a common lineage relationship, reflective of spatial constraints during tumor 
expansion. SSNVs in known and candidate driver genes are labeled. A truncal APC 
indel was also detected, but not used for tree construction. 
 
Figure 5. The SFS reflects differential modes of evolution within and between 
tumors types. (a) Cumulative SFS based on the merged VAF for tumors derived from 
four tissue types (colon, esophageal, lung, brain) analyzed using the VAP (Methods). All 
samples were subject to WES with the exception of the ESCA/BE cases for which WGS 
was available. Each line corresponds to a Bezier smoothed curve of the cumulative 
SFS. Thick gray curves correspond to the theoretical cumulative SFS under neutral 
exponential growth in a well-mixed population, shown for reference. Dashed lines 
correspond to comparisons of tumor regions sampled at distinct stages of tumor 
progression in the same patient, e.g., Barrett's esophagus (BE) versus esophageal 
carcinoma (ESCA), or treatment naïve primary tumor versus post-treatment (Tx) 
recurrent brain tumors, both of which represent positive controls for selection.  (b) 
Pairwise SFS histograms from representative tumors of different tissue origin depict the 
number of SSNVs detected at a given VAF for two regions, where SSNVs are grouped 
into Public (gray), Private (Pvt)-Shared (green) and Private-Region specific (blue) 
mutations (as in Figure 3). Histogram bin widths were optimized based on the number 
of SSNVs (Methods). (c) Two-way density plots of SSNVs present in each region at a 
given VAF are shown for two tumors exhibiting signals of selection. Non-silent SSNVs in 
known and candidate driver genes are labeled. The color scale represents the relative 
	 21	
density of mutations. 
 
Figure 6:  Projection of patient samples onto distinct evolutionary modes. (a) 
Violin plots for each of five ITH metrics, namely, fHsub, fHrs, Fst, KSD, and rAUC. 
Colored violin plots show the tumors simulated under different evolutionary modes, 
whereas the white plots represent real tumor data. Paired pre-treatment primary and 
post-treatment recurrent brain tumors are denoted by “Tx” and serve as a positive 
control for selection.  (b) Independent component analysis (ICA) of simulated and real 
tumors based on the five ITH metrics. The independent components clearly separate 
the simulated tumors under effectively (e) neutral growth (neutral, neutral-CSC and 
s=0.01) versus positive selection (s≥0.02). The decision boundary for an SVM trained 
on the two independent components (IC) based on the virtual tumors (e-neutral versus 
positive selection models) is indicated by the dashed line. Large transparent colored 
circles represent values from simulated tumors under different models (200 tumors from 
each of the seven modes are shown). Small circles corresponding to patient tumors are 
labeled by their corresponding sample ID, and color-coded according to the nature of 
the samples. COAD: colorectal adenocarcinoma; CRA: colorectal adenoma; ESCA: 
esophageal adenocarcinoma; BE: Barrett's esophagus; LUAD: lung adenocarcinoma; 
NSCLC: non-small-cell lung cancer; GLM: glioma; GBM: glioblastoma; Xeno: COAD cell 
line xenografts. (c) The ratio of private SSNVs at more functional (MF) relative to less 
functional (LF) sites (dMF/dLF) as defined based on PolyPhen2 was calculated for each 
of the primary tumors in order to evaluate the correlation with various ITH. 
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